Press Releases

Date	Title	Company
26-Oct-2023	GALDERMA PHASE III DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: FULL OLYMPIA 2 TRIAL RESULTS DEMONSTRATE NEMOLIZUMAB’S RAPID ONSET OF ACTION IN PRURIGO NODULARIS PATIENTS	Galderma
26-Oct-2023	AlzeCure presents disease-modifying data with NeuroRestore ACD856 at Alzheimer's conference CTAD	AlzeCure
26-Oct-2023	Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	Immunocore
26-Oct-2023	ALTURiX Introduces CEYESTO® Melatonin Oral Solution In The UK Featuring A Diverse Set Of Approved Indications - Two Of Which Are World-First	ALTURiX
26-Oct-2023	Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations	Mainz BioMed N.V.
26-Oct-2023	Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA	Newswire
26-Oct-2023	KITE’S CAR T-CELL THERAPY YESCARTA® (AXICABTAGENE CILOLEUCEL) COMPARED WITH BISPECIFICS IN R/R DLBCL IN TWO ANALYSES AT ESMO 2023	Kite
26-Oct-2023	An innovative pilot designed to support patients to get better outcomes from their medicine has shown early success	Sciensus
26-Oct-2023	Kancera reports that the phase I study of KAND145 has received regulatory approval	Kancera AB
26-Oct-2023	Landmark Phase 3 MARIPOSA Study Shows RYBREVANT®▼(amivantamab) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Phase 3 MARIPOSA-2 Study Shows RYBREVANT®▼(amivantamab) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFRMutated Non-Small Cell Lung Cancer who Progressed on or after Osimertinib	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Cytomos selected to showcase CDS cell analysis technology at BIA’s BioProcessUK Dragon’s Den session	Cytomos
26-Oct-2023	ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment	ViiV Healthcare
26-Oct-2023	PAION AG: Filing an application for the opening of insolvency proceedings	PAION AG
26-Oct-2023	GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100	GPCR Therapeutics
26-Oct-2023	Mtech Access are returning to ISPOR Europe this November	Mtech Access
26-Oct-2023	Over half of Brits may have high cholesterol. Will ending ‘bad’ cholesterol testing add to the problem?	London Medical Laboratory
26-Oct-2023	Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona	Lubrizol Life Science Health
26-Oct-2023	Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers	Oxford BioTherapeutics
26-Oct-2023	Aptar Digital Health Announces Stallergenes Greer Launch of iPUMP® in France, the First Connected Allergy Management Assistant	Aptar Digital Health